PMV Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(18,038) | $(17,436) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 1,392 | 1,508 |
| Depreciation | 34 | 37 |
| Accretion of discounts on marketable securities | (385) | (840) |
| Non cash lease income | (2) | (2) |
| Gain on termination of lease, net | (24) | — |
| Loss on sales and disposals of fixed assets, net | — | 4 |
| Other, net | 1 | (2) |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 53 | 3,088 |
| Accounts payable | (1,524) | (2,986) |
| Accrued expenses | (1,186) | (1,637) |
| Net cash used in operating activities | (19,679) | (18,266) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (4) |
| Purchases of marketable securities | (10,676) | (15,727) |
| Maturities of marketable securities | 31,500 | 44,445 |
| Net cash provided by investing activities | 20,824 | 28,714 |
| Cash flows from financing activities: | ||
| Proceeds from the exercise of stock options | — | 10 |
| Net cash provided by financing activities | — | 10 |
| Impact of exchange rates on cash, cash equivalents, and restricted cash | 2 | 7 |
| Net increase in cash and cash equivalents | 1,147 | 10,465 |
| Cash, cash equivalents, and restricted cash | ||
| Cash, cash equivalents, and restricted cash - beginning of period | 37,983 | 40,876 |
| Cash, cash equivalents, and restricted cash - end of period | $39,130 | $51,341 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.